z-logo
Premium
Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit‐isolated methicillin‐resistant Staphylococcus aureus
Author(s) -
Salem Ahmed Hamed,
Zhanel George G,
Ibrahim Safaa A,
Noreddin Ayman M
Publication year - 2014
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12195
Subject(s) - daptomycin , dalbavancin , tigecycline , linezolid , vancomycin , medicine , pharmacodynamics , methicillin resistant staphylococcus aureus , pharmacology , staphylococcus aureus , pharmacokinetics , antibiotics , microbiology and biotechnology , biology , bacteria , genetics
Summary The aim of the present study was to compare the potential of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin to achieve their requisite pharmacokinetic/pharmacodynamic ( PK / PD ) targets against methicillin‐resistant Staphylococcus aureus isolates collected from intensive care unit ( ICU ) settings. Monte Carlo simulations were carried out to simulate the PK / PD indices of the investigated antimicrobials. The probability of target attainment ( PTA ) was estimated at minimum inhibitory concentration values ranging from 0.03 to 32 μg/mL to define the PK / PD susceptibility breakpoints. The cumulative fraction of response ( CFR ) was computed using minimum inhibitory concentration data from the Canadian National Intensive Care Unit study. Analysis of the simulation results suggested the breakpoints of 4 μg/mL for ceftobiprole (500 mg/2 h t.i.d.), 0.25 μg/mL for dalbavancin (1000 mg), 0.12 μg/mL for daptomycin (4 mg/kg q.d. and 6 mg/kg q.d.) and tigecycline (50 mg b.i.d.), and 2 μg/mL for linezolid (600 mg b.i.d.) and vancomycin (1 g b.i.d. and 1.5 g b.i.d.). The estimated CFR were 100, 100, 70.6, 88.8, 96.5, 82.4, 89.4, and 98.3% for ceftobiprole, dalbavancin, daptomycin (4 mg/kg/day), daptomycin (6 mg/kg/day), linezolid, tigecycline, vancomycin (1 g b.i.d.) and vancomycin (1.5 g b.i.d.), respectively. In conclusion, ceftobiprole and dalbavancin have the highest probability of achieving their requisite PK / PD targets against methicillin‐resistant Staphylococcus aureus isolated from ICU settings. The susceptibility predictions suggested a reduction of the vancomycin breakpoint to 1 μg/mL.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom